Sionna Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary
Sionna Therapeutics reported a wider net loss of $32.42M in Q3 2026, up 59.9% YoY, due to increased R&D and administrative expenses. The company selected SION-451 + SION-2222 for its dual combination program but will not advance SION-719 after a failed trial. It reduced its workforce by 46% and expects its cash runway to extend into 2H 2029.
How this was made

The 30-second read
Why it matters
The earnings miss and trial setback are likely to depress the stock in the short term.
Market read
Primary earnings disclosure for a micro‑cap biotech; negative catalyst for the stock.
What to watch
Potential upside from the dual‑combination program SION-451 + SION-2222 entering Phase 2.
Background
Sionna Therapeutics filed its Q3 2026 10‑Q, reporting widened losses and a failed add‑on trial.
Ticker impact
Q3 net loss widened to $32.42M and diluted EPS fell to -$0.72 versus the prior quarter.
downward pressure as investors price in the larger loss and trial failure
Earnings miss and a failed Phase 2a trial are material negative catalysts for a biotech.
Market effects
Biotech sector may see modest pullback as trial failures raise risk perception.
U.S. biotech investors may adjust exposure; limited broader market effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The restructuring and cash runway to 2029 could support a longer‑term rebound.
Key entities
- companySionna Therapeutics
Biotech firm reporting Q3 2026 results.
